Emergent BioSolutions Inc. — Director's Dealing 2016

Mar 12, 2016

SEC Form 4/A — Form 4/A

Issuer: Emergent BioSolutions Inc. (EBS)
CIK: 0001367644
Period of Report: 2016-03-01

Reporting Person: El-Hibri Fuad (Director, Chairman, 10% Owner)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2016-03-01	Restrictive Stock Units	$	A	26303	Acquired		Common Stock (26303)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	1771605	Direct
Common Stock	2350331	Indirect
Common Stock	1524155	Indirect

Footnotes

F1: This form 4 is being amended to reflect a change in reporting convention by backing out from Table I Mr. El-Hibri's unvested restricted stock units. Such unvested restricted stock units are instead reported on Table II. The 1,771,605 shares of securities beneficially owned directly by Mr. El-Hibri does not include unvested restricted stock units.

F2: Mr. El-Hibri's holdings through Intervac, L.L.C. include 1,638,403 shares of Common Stock held by Mr. El-Hibri and his wife, as tenants by the entirety, through their 37.7% equity interest in Intervac, L.L.C.; 127,721 shares held by Mr. El-Hibri's wife; and 584,207 shares held by trusts indirectly controlled by Mr. El-Hibri or his wife. Mr. El-Hibri disclaims beneficial ownership, for purposes of Section 16 of the Exchange Act or otherwise, of those shares held solely by his wife and those shares held by the trusts.

F3: Mr. El-Hibri holds individually and with his wife, as tenants by the entirety, an aggregate 89.2% equity interest in Biovac, L.L.C. Biovac, L.L.C. is the direct owner of 1,524,155 shares of Common Stock. Mr. El-Hibri disclaims beneficial ownership of the shares of Common Stock directly owned by Biovac, L.L.C. for purposes of Section 16, except to the extent of his pecuniary interest in 1,359,546 shares.
This number corrects a historical scrivener's error that occurred more than two years ago. Prior to the transaction reported herein, for purposes of Section 16 of the Exchange Act, Mr. El-Hibri directly held a pecuniary interest in 1,771,605 shares of Common Stock.

F4: This form 4 is being amended to reflect a change in reporting convention. The restrictive stock units set forth in Table II reflect Mr. El Hibri's unvested RSUs that were backed out of Table I.

F5: Each restricted stock unit represents the right of Mr. El-Hibri to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement.

F6: The restricted stock units and options vest in three equal installments on February 28, 2017, February 28, 2018 and February 28, 2019.